In January 2016, Independence Blue Cross and NantHealth announced the nation's first coverage for a whole genome sequencing and proteome molecular diagnostic platform, but it's mostly slipped under the radar since then. What's going on?
Lower costs for capital and sequencing, a friendlier regulatory and reimbursement environment and growth in precision medicine are among driving factors.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Forecast of significant growth in market comes after Roche acquired remaining stake in Foundation Medicine last month.
It's the latest in a series of companies Roche has acquired to add services and technology to the Big Pharma's drug development business, particularly in cancer treatment.
Michael Pellini, the featured speaker at MedCity's CONVERGE conference next month, holds forth on his new VC gig at Bill Maris-founded Section 32, the practice of oncology, and how healthcare must get more tightly integrated with tech.
The company plans to bring NGS to health systems lacking the ability to perform it internally.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
If approved, LOXO-101 (larotrectinib) would be the second drug to win a biomarker-based label, after Merck's Keytruda.
Companies to create tests for tissue-agnostic MSI-H and dMMR cancers using Foundation's next-generation sequencing platform.
Next-generation sequencing firm plans to present data on its gargantuan genomics study at ASCO next month.
Foundation Medicine and ThermoFisher Scientific are big beneficiaries of CMS widening its coverage and making a national coverage decision for next-generation sequencing of metastatic, Stage 3 or 4 and other cancers.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
FDA approves the first-of-its-kind large-panel genetic diagnostic test from Foundation Medicine with CMS offering a preliminary National Coverage Decision on it. Commercial insurers so far have preferred to cover diagnostics tests that target a single or a handful genes.
FDA approval would set a molecular test apart, said Vince Miller, Foundation Medicine’s chief medical officer. “CLIA is the floor, New York State is a number of floors above that and the FDA is the penthouse.”
A family member's liquid biopsy test, gene testing and a journey into coverage decisions and clinical guidelines reveal how difficult the reimbursement path is for these emerging technologies.
At an industry conference hosted by the largest medtech lobby, CMS officials hint that they have arrived at a decision regarding Foundation Medicine's genetic test.
On the back of that symbolic FDA approval, Foundation Medicine's Gaurav Singal discussed the latest innovations for expanding access to precision medicine beyond the major academic centers.